AIDP, Inc., the distributor of Magtein™ magnesium L-threonate, a new discovery in the brain health category for cognitive health; KoACT®, a patented chelated compound of calcium and hydrolyzed collagen peptides; and enVantec™, a proprietary micro-encapsulation technology, has announced that it has retained Pathway International Pty Ltd. to represent AIDP branded products in Australia and New Zealand. Pathway International will be the exclusive agent for both territories, initially focusing on Magtein, KoACT and enVantec.
According to Kathy Lund, AIDP director of business development, Pathway International was selected because they are a functional ingredients leader with vast experience in bringing branded products to the Southern hemisphere. Pathway International currently is seeking to secure TGA approval from the Therapeutic Goods Administration (TGA) in Australia for all three products.
“The market is well developed, growing and open to new products,” says Lund. “We’re on the door step of TGA approval for Magtein and enVantec and convinced these branded products will be well received in Australia and New Zealand.
“Furthermore, while we can’t place a dollar amount on this expansion, according to a recent article in Australia’s Daily Telegraph, despite the impact of ongoing global uncertainty and uneven conditions across sectors, the International Monetary Fund expects the Australian economy will outpace all major advanced economies over the next two years, and forecasts growth of 3.0% in 2012 and 3.5% in 2013,” noted Lund. “So we think this is a good place for brand expansion.”
“We are delighted to represent AIDP in the ANZ markets for their branded ingredients which have novel and interesting applications,” said Wayne Coote, managing director for Australia-based Pathway International Pty Ltd.
For the last 17 years, Pathway has been a leading supplier to the Australian and New Zealand markets for specialty healthcare ingredients. Pathway now represents more than 30 manufacturers of branded active ingredients with clinical studies to support the dietary supplement and food and beverage markets. The Pathway website is www.Pathway.net.au.
“Pathway is positioned to undertake the required regulatory work for these ingredients and has a proven track record in this process. While we’re waiting for TGA approval, we have time to work with our customers in parallel with this process. Furthermore, future market launches will be planned to coincide with the final TGA approval,” added Coote.